Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Worldwide Pharma Operations Report To Burns: U.S. & Licensing Added

Executive Summary

Roche Head of Pharma International Operations William Burns is adding oversight responsibilities for the U.S. drug business and licensing activities as part of his new job as worldwide head of pharmaceuticals.

You may also be interested in...



Roche U.S. CEO Zenner Retiring In January; Successor Not Yet Named

Roche is varying from its decades long pattern of carefully choreographed management transitions by leaving open the succession plan for U.S. CEO Patrick Zenner.

Roche U.S. CEO Zenner Retiring In January; Successor Not Yet Named

Roche is varying from its decades long pattern of carefully choreographed management transitions by leaving open the succession plan for U.S. CEO Patrick Zenner.

Roche Kytril Acquisition From SmithKline Strengthens Hospital Focus In U.S.

Roche's acquisition of the anti-emetic Kytril from SmithKline Beecham will build on Roche's strength in the U.S. hospital market.

Related Content

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel